These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11215308)

  • 1. Adrenocorticotropic hormone and growth factor receptors in breast cancer.
    Ray A; Ratnakar N; Murthy NS; Sharma BK
    Indian J Exp Biol; 2000 Jul; 38(7):663-8. PubMed ID: 11215308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
    Looi LM; Cheah PL
    Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix.
    Ray A; Naik SL; Sharma BK
    Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
    Sharma BK; Ray A; Kaur S; Gupta S
    Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer.
    Ray A; Sharma BK; Kaur S; Sharma S; Sharma JK
    Indian J Exp Biol; 2004 Mar; 42(3):253-8. PubMed ID: 15233293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes.
    Harłoziñska A; Bar JK; Wenderski R; Bebenek M
    In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenocorticotropic hormone production in breast cancer.
    Poddar NK; Saha R; Hedau S; Ray A
    Indian J Exp Biol; 2005 Jan; 43(1):35-9. PubMed ID: 15691063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression.
    Spaventi R; Kamenjicki E; Pecina N; Grazio S; Grazio S; Pavelic J; Kusic B; Cvrtila D; Danilovic Z; Spaventi S
    In Vivo; 1994; 8(2):183-9. PubMed ID: 7919121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
    Kolár Z; Murray PG; Zapletalová J
    Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
    Looi LM; Cheah PL; Yap SF
    Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
    Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
    Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study.
    Bianchi S; Palli D; Falchetti M; Saieva C; Masala G; Mancini B; Lupi R; Noviello C; Omerovic J; Paglierani M; Vezzosi V; Alimandi M; Mariani-Costantini R; Ottini L
    J Cell Physiol; 2006 Mar; 206(3):702-8. PubMed ID: 16245316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGF-R expression in ductal breast cancer: proliferation and prognostic implications.
    Bucci B; D'Agnano I; Botti C; Mottolese M; Carico E; Zupi G; Vecchione A
    Anticancer Res; 1997; 17(1B):769-74. PubMed ID: 9066618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.